De BacquerDde SmedtDReiner Ž, et al.Percentual LDL-C response to a given statin dose is not fixed across the pre-treatment range: Real world evidence from clinical practice: Data from the ESC-EORP EUROASPIRE V study. Eur J Prev Cardiol. Epub ahead of print 9 September 2019. DOI: 10.1177/2047487319874898.
2.
KarlsonBWWiklundOPalmerMK, et al.Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: Results from VOYAGER. Eur Heart J Cardiovasc Pharmacother2016; 2: 212–217.
3.
Pedro-BotetJSchaeferEJBakker-ArkemaRG, et al.Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis2001; 158: 183–193.
4.
MassonMLoboMMaenentD, et al.Response to statins in cardiovascular prevention: Hypo-responders’ evaluation. Rev Argent Cardiol2014; 82: 34–41.
5.
MarrettEZhaoCZhangNJ, et al.Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US. Vasc Health Risk Manag2014; 10: 237–246.
6.
LinISungJSanchezRJ, et al.Patterns of statin use in a real-world population of patients at high cardiovascular risk. J Manag Care Spec Pharm2016; 22: 685–698.
7.
RuokoniemiPSundRArffmanM, et al.Are statin trials in diabetes representative of real-world diabetes care: A population-based study on statin initiators in Finland. BMJ Open2014; 4: e005402–e005402.
8.
AlterDATuJVKohM, et al.Projected real-world effectiveness of using aggressive low-density lipoprotein cholesterol targets among elderly statin users following acute coronary syndromes in Canada. J Am Heart Assoc2018; 7: e007535–e007535.
9.
RizzoMBanachMMontaltoG, et al.Lipid-lowering therapies and achievement of LDL-cholesterol targets. Arch Med Sci2012; 8: 598–600.
10.
MachFRayKKWiklundO, et al.European Atherosclerosis Society Consensus Panel. Adverse effects of statin therapy: Perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J2018; 39: 2526–2539.
11.
KlingmanDWilliamsSABennerJS, et al.Gauging the treatment gap in dyslipidemia: Findings from the 1999–2000 National Health and Nutrition Examination Survey. Am Heart J2005; 150: 595–601.
12.
Bielecka-DabrowaAAronowWSRyszJ, et al.The rise and fall of hypertension: Lessons learned from Eastern Europe. Curr Cardiovasc Risk Rep2011; 5: 174–179.
